All the publications authored by Dr. Giovannetti (until december 2019)


(see also:

  1. Frampton AE, Giovannetti E. Diagnosing pancreatic ductal adenocarcinoma using plasma extracellular vesicle RNA profiles. Gut. 2019 [Epub ahead of print]
  2. Durovski D, Randazzo O, Peters GJ, Giovannetti E. Role of Developmental Signaling Pathways in Non-Small Cell Lung Carcinoma. J Mol Clin Med 2019;2:41-53
  3. Meijer LL, Zwart ES, Brandt BW, Mebius R, Deng D, Giovannetti E,* Zaura E, Kazemier G. Tumor microbiome: Pancreatic cancer and duodenal fluids contain multitudes, …but do they contradict themselves? Crit Rev Oncol Hematol. 2019;144:102824. (*corresponding author)
  4. Capula M, Mantini G, Funel N, Giovannetti E. New avenues in pancreatic cancer: exploiting microRNAs as predictive biomarkers and new approaches to target aberrant metabolism. Expert Rev Clin Pharmacol. 2019 Nov 24:1-10.
  5. Leonetti A, Boyd L, Giuliani J, Giovannetti E, *Garajová I. Light and shadow on innovative clinical trial designs: reflections from the EORTC-PAMM course on ‘preclinical and early-phase clinical pharmacology’. Expert Rev Clin Pharmacol. 2019;12(11):1033-1036.
  6. Leonetti A, Wever B, Mazzaschi G, Assaraf YG, Rolfo C, Quaini F, Tiseo M, Giovannetti E. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. Drug Resist Updates 2019; 46:100644.
  7. Leonetti A, Van der Steen N, Peters GJ, Rolfo C, Tiseo M, Giovannetti E. Can we optimize the selection of lung cancer patients suitable for EGFR+MET double inhibition? JCO Precision Oncology 2019;3:1-2
  8. Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E*, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.  (*corresponding author) Br J Cancer 2019; 121(9):725-737.
  9. Mousavi F, Saso L, Giovannetti E, Firuzi O. HGF/MET pathway aberrations as diagnostic, prognostic and predictive biomarkers in human cancers. Crit Rev Clin Lab Sci. 2019;56(8):533-566.
  10. Cretella D, Di Giacomo G, Giovannetti E*, Cavazzoni A. PTEN alterations as a potential mechanism for tumor cell escape from PD-1/PD-L1 inhibition. (*corresponding author) Cancers 2019;11(9). pii: E1318. doi: 10.3390/cancers11091318
  11. El Hassouni B, Granchi C, Vallés-Martí A, I Supadmanaba GP, Bononi G, Tuccinardi T, Funel N, Peters GJ, Jimenez CR, Giovannetti E*, Minutolo F* The Dichotomous Role of the Glycolytic Metabolism Pathway in Cancer Metastasis: Interplay with the Complex Tumor Microenvironment and Novel Therapeutic Strategies. Sem Cancer Biol Oncology 2019:pii: S1044-579X(19)30180-4. (*equally contributed)
  12. Codacci-Pisanelli G, Assalin N, Honeyweel R, Peters GJ, Giovannetti E*, Peccatori F* (*equally contributed) Breastfeeding during R-CHOP chemotherapy: please abstain! Eur J Cancer 2019; 19;119:107-111.
  13. Meijer LL, Puik J, Le Large TYS, Heger M, Dijk F, Funel N, Wurdinger T, Garajova I, van Grieken NCT, van de Wiel M, Giovannetti E*, Kazemeier G*. Unravelling the diagnostic dilemma: A microRNA panel of circulating miR-16 and miR-877 as a diagnostic classifier for distal bile duct tumors. Cancers, 2019 Aug 15;11(8). doi: 10.3390/cancers11081181. (*equally contributed)
  14. Carnevale I, Capula M, Giovannetti E, Schmidt T, Coppola S. A mechanical memory of pancreatic cancer cells. Reprint 10.1101/730960 posted on bioRxiv:
  15. Le Large TYS, El Hassouni B, Funel N, Kok B, Piersma SR, Pham TV, Olive KP, Kazemier G, van Laarhoven HWM, Jimenez CR, Bijlsma MF, Giovannetti E. Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment. Ther Advances Med Oncol 2019;11:1758835919841233;
  16. Roos E, Soer EC, Klompmaker S, Meijer LL, Besselink MG, Giovannetti E, Heger M, Kazemier G, Klümpen HJ, Takkenberg RB, Wilmink H, Würdinger T, Dijk F, van Gulik TM, Verheij J, van de Vijver MJ. Crossing borders: A systematic review with quantitative analysis of genetic mutations of carcinomas of the biliary tract. Crit Rev Oncol Hematol. 2019;24;140:8-16.
  17. Van Der Steen N, Leonetti A, Keller K, Dekker H, Funel N, Lardon F, Ruijtenbeek R, Tiseo M, Rolfo C, Pauwels P, Peters GJ, Giovannetti E. Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line. Biochem Pharmacol. 2019;166:128-138.
  18. Firuzi O, Che PP, El Hassouni B, Buijs M, Coppola S, Löhr M, Funel N, Heuchel R, Carnevale I, Schmidt T, Mantini G, Avan A, Saso L, Peters GJ, Giovannetti E. Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells. Cancers (Basel) 2019;11(5)
  19. Leonetti A, Facchinetti F, Minari R, Cortellini A, Rolfo CD, Giovannetti E, Tiseo M. Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges. Cell Oncol (Dordr) 2019;42(3):261-273.
  20. Balboni B, El Hassouni B, Sarkisjan D, Honeywell R, Giovannetti E, Peters GJ. RX-3117 (fluorocyclopentenyl cytosine), a novel specific antimetabolite for selective cancer treatment. Exp Opin Invest New Drugs 2019;28(4):311-322.
  21. Cascioferro S, Parrino B, Petri GL, Cusimano MG, Schillaci D, Di Sarno V, Musella S, Giovannetti E, Cirrincione G, Diana P. 2,6-Disubstituted imidazo[2,1-b][1,3,4]thiadiazole derivatives as potent staphylococcal biofilm inhibitors. Eur J Med Chem 2019;167:200-210.
  22. Sciarrillo R, Wojtuszkiewicz A, El Hassouni B, Funel N, Gandellini P, Lagerweij T, Buonamici S, Blijlevens M, Zeeuw van der Laan EA, Zaffaroni N, Deraco M, Kusamura S, Würdinger T, Peters GJ, Molthoff CFM, Jansen G, Kaspers GJL, Cloos J, Giovannetti E. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma. EBioMedicine. 2019;39:215-225.
  23. El Hassouni B, Sarkisjan D, Vos JC, Giovannetti E, Peters GJ. Targeting the ribosome biogenesis key molecule fibrillarin to avoid chemoresistance. Curr Med Chem [Epub ahead of print] doi: 10.2174/0929867326666181203133332. [Epub ahead of print]
  24. Li Petri G, Cascioferro S, El Hassouni B, Carbone D, Parrino B, Cirrincione G, Peters GJ, Diana P, Giovannetti E. Biological Evaluation of the Antiproliferative and Anti-migratory Activity of a Series of 3-(6-Phenylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-1H-indole Derivatives Against Pancreatic Cancer Cells. Anticancer Res. 2019;39(7):3615-3620.
  25. El Hassouni B, Infante J, Mantini G, Ricci C, Funel N, Giovannetti E, Peters GJ. Uridine Cytidine Kinase 2 as a Potential Biomarker for Treatment with RX-3117 in Pancreatic Cancer. Anticancer Res. 2019;39(7):3609-3614.
  26. El Hassouni B, Mantini G, Li Petri G, Capula M, Boyd L, Weinstein HNW, Vallés-Marti A, Kouwenhoven MCM, Giovannetti E, Westerman BA, Peters GJ; EORTC PAMM Group. To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology. Anticancer Res. 2019;39(7):3303-3309.
  27. Liu DSK, Mato Prado M, Giovannetti E, Jiao LR, Krell J, Frampton AE. Can circulating tumor and exosomal nucleic acids act as biomarkers for pancreatic ductal adenocarcinoma? Expert Rev Mol Diagn. 2019;19(7):553-558.
  28. El Hassouni B, Li Petri G, Liu D, Cascioferro S, Parrino B, Hassan W, Diana P, Ali A, Frampton AE, Giovannetti E. Pharmacogenetics of treatments for pancreatic cancer. Expert Opin Drug Metab Toxicol. 2019;15(6):437-447.
  29. Van Den Borg R, Leonetti A, Tiseo M, Giovannetti E, Peters GJ. Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine. Expert Rev Anticancer Ther. 2019;19(6):461-471.
  30. Peters GJ, Honeywell RH, Giovannetti E, Ciccolini J. Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response? Brit J Clin Pharmacol 2019; 85(6):1213-1214.
  31. Meijer LL, Garajova I, Caparello C, Le Large TY, Frampton A, Vasile E, Funel N, Kazemier G, Giovannetti E (2018) Plasma miR-181a-5p Down-Regulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma. Ann Surgery 2019 [Epub ahead of print] doi: 10.1097/SLA.0000000000003084. [Epub ahead of print]
  32. Parrino B, Schillaci D, Carnevale I, Giovannetti E Diana P, Cirrincione G, Cascioferro S. Anti-biofilm Agents in the Struggle against Antibiotic Resistance. Eur J Med Chem 2019;161:154-178.
  33. Leonetti A, Assaraf YG, Veltsista PD, El Hassouni B, Tiseo M, Giovannetti E. MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: current implications and future directions. Drug Resist Updates 2019;42:1-11
  34. Choy ATF, Carnevale I, Coppola S, Meijer LL, Kazemier G, Zaura E, Deng D, Giovannetti E. The microbiome of pancreatic cancer: from molecular diagnostics to new therapeutic approaches to overcome chemoresistance caused by metabolic inactivation of gemcitabine. Expert Rev Mol Diagn. 2018;18(12):1005-1009
  35. Tibaldi C, Camerini A, Tiseo M, Mazzoni F, Barbieri F, Vittimberga I, Brighenti M, Boni L, Baldini E, Gilli A, Honeywell R, Chartoire M, Peters GJ, Giovannetti E. Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced Non-Small-Cell Lung Cancer: a prospective validation study. Br J Cancer 2018;119(11):1326-1331.
  36. Le Large TY, El Hassouni B, Kazemier G, Bijlsma MF, Piersma S, van Laarhoven HM, Jimenez CR Giovannetti E. (2018) Letter to the editor: multi-drug resistant transporter expression does not always result in drug resistance. Cancer Sci 2018;109(10):3360-3362.
  37. Santapia MC, Funel N, Ali A, Giovannetti E. Liquid biopsies to optimize therapeutic efficacy in unresponsive lung cancer patients. Expert Opin Drug Metab Toxicol. 2018;14(8):761-763
  38. Li Petri G, Cascioferro S, Parrino B, Peters GJ, Diana P, Giovannetti E. PCFT as a biomarker of outcome to treatment for pleural mesothelioma. Pharmacogenomics 2018;19(10):811-814.
  39. Ottaviani S, Stebbing J, Frampton AE, Krell J, de Giorgio A, Trabulo SM, Nguyen VTM, Magnani L, Giovannetti E, Funel N, Gress TM, Jiao LR, Lombardo Y, Heeschen C, Castellano L. TGF-ß induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling EMT and stemness. Nat Comm 2018;9(1):1845
  40. Frampton AE, Mato Prado, Lopez-Jimenez E, Fajardo-Puerta AB, Jawad ZAR, Lawton P, Elisa Giovannetti E, Habib NA, Castellano L, Stebbing J, Krell J, Jiao LR. Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden. Oncotarget 2018;9(27):19006-19013.
  41. van Zweeden AA, van Groeningen CJ, Honeywell RJ, Giovannetti E, Ruijter R, Smorenburg CH, Giaccone G, Verheul HMW, Peters GJ, van der Vliet HJ. Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer. Cancer Chem Pharmacol 2018;82(1):39-48.
  42. Passiglia F, Caglevic C, Giovannetti E, Pinto JA, Manca P, Taverna S, Listìa A, Gil-Bazo I, Raez LE, Russo A, Rolfo C. Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment. Sem Cancer Biol 2018;52(Pt 2):259-268
  43. Toffalorio F, Santarpia MC, Radice D, Jaramillo CA, Spitaleri G, Manzotti M, Catania C, Jordheim LP, Pelosi G, Peters GJ, Tibaldi C, Funel N, Spaggiari L, de Braud F, De Pas T, Giovannetti E. 5′-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/ platinum combination chemotherapy in non-small cell lung cancer. Oncotarget 2018;9(23):16437-16450
  44. Rolfo C, Giovannetti E. A synthetic lethal bullet. Nat Nanotech 2018;13(1):6-7.
  45. Van Der Steen N, Mentens Y, Ramael M, Leon LG, Germonpré P, Ferri J, Gandara DR, Giovannetti E, Peters GJ, Pauwels P, Rolfo C. Double trouble: a case series on concomitant genetic aberrations in NSCLC. Clin Lung Cancer 2018;19(1):35-41.
  46. Garajova I, Balsano R, Tommasi C, Giovannetti E. Noncoding RNAs emerging as novel biomarkers in pancreatic cancer. Curr Pharm Des. 2018;24(39):4601-4604.
  47. Lazzari C, Gregorc V, Cangi MG, Giovannetti E, Bulotta A, Santarpia M. Combined exosomal RNA and circulating tumor DNA for epidermal growth factor mutation detection in non-small cell lung cancer. J Thorac Dis 2018;10(Suppl 33):S4023-S4027. doi: 10.21037/jtd.2018.10.17
  48. Van Meerbeeck JP, Jansen G, Giovannetti E, Peters GJ. Aminopeptidase inhibitors in mesothelioma: which sacks for this new wine? Eur J Resp Dis 2018; 51: 1800817
  49. Van Der Steen N, Giovannetti E, Carbone D, Leonetti A, Rolfo CD, Peters GJ. Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer. Cancer Drug Resist 2018;1:230-249.
  50.  Giovannetti E, Rodriguez JA. Targeted therapies in cancer: where are we going? Cancer Drug Resist 2018;1:82-86.
  51. Van Der Steen N, Honeywell RJ, Dekker H, Van Meerloo J, Kole J, Musters R, Ruijtenbeek R, Rolfo C, Pauwels P, Peters GJ, Giovannetti E. Resistance to crizotinib in a cMET gene amplified tumor cell line is associated with impaired sequestration of crizotinib in lysosomes. J Mol Clin Med 2018(Vol 1):102-105
  52. Holst S, Belo AI, Giovannetti E, van Die I, Wuhrer M. Profiling of different pancreatic cancer cells used as models for metastatic behaviour shows large variation in their N-glycosylation. Sci Rep. 2017;7:16623.
  53. Giovannetti E, Zucali PA, Assaraf YG, Funel N, Gemelli M, Stark M, Thunnissen E, Hou Z, Muller IB, Struijs EA, Perrino M, Jansen G, Matherly LH, Peters GJ. Role of proton-coupled folate transporter in pemetrexed-resistance of mesothelioma: clinical evidence and new pharmacological tools. Ann Oncol. 2017;28(11):2725-2732.
  54. Coppola S, Carnevale I, Danen EHJ, Peters GJ, Schmidt T, Assaraf YG, Giovannetti E. A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer. Drug Resist Updates 2017;31:43-51.
  55. Alfieri R, Giovannetti E, Bonelli M, Cavazzoni A. New treatment opportunities in PTEN-deficient tumors: focus on PTEN/FAK pathway. Front Oncol (section Molecular and Cellular Oncology) 2017;7:170.
  56. Puik JR, Meijer LL, Le Large TY, Prado MM, Frampton AE, Kazemier G, Giovannetti E. miRNA profiling for diagnosis, prognosis and stratification of cancer treatment in cholangiocarcinoma. Pharmacogenomics. 2017;18(14):1343-1358.
  57. Best MG, Sol N, In ‘t Veld SGJG, Vancura A, Muller M, Niemeijer AN, Fejes AV, Tjon Kon Fat LA, Huis In ‘t Veld AE, Leurs C, Le Large TY, Meijer LL, Kooi IE, Rustenburg F, Schellen P, Verschueren H, Post E, Wedekind LE, Bracht J, Esenkbrink M, Wils L, Favaro F, Schoonhoven JD, Tannous J, Meijers-Heijboer H, Kazemier G, Giovannetti E, Reijneveld JC, Idema S, Killestein J, Heger M, de Jager SC, Urbanus RT, Hoefer IE, Pasterkamp G, Mannhalter C, Gomez-Arroyo J, Bogaard HJ, Noske DP, Vandertop WP, van den Broek D, Ylstra B, Nilsson RJA, Wesseling P, Karachaliou N, Rosell R, Lee-Lewandrowski E, Lewandrowski KB, Tannous BA, de Langen AJ, Smit EF, van den Heuvel MM, Wurdinger T. Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets. Cancer Cell. 2017;32(2):238-252.e9
  58. Van Der Steen N, Rolfo C, Pauwels P, Peters GJ, Giovannetti E. Resistance mechanisms to AZD9291 and Rociletinib – Letter. Clin Cancer Res 2017;23(14):3966.
  59. Cavazzoni A, La Monica S, Alfieri R, Ravelli A, Van Der Steen N, Sciarrillo R, Madeddu D, Lagrasta C, Quaini F, Bonelli M, Fumarola C, Cretella D, Digiacomo G, Tiseo M, Peters GJ, Ardizzoni A, Petronini PG, Giovannetti E. Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN. Oncotarget 2017;8(32):53068-83.
  60. Grasso C, Jansen G, Giovannetti E. Drug resistance in pancreatic cancer: Impact of altered energy metabolism. Crit Rev Oncol Hematol 2017;114:139-152
  61. van Beijnum JR, Giovannetti E, Poel D, Nowak-Sliwinska P, Griffioen AW. miRNAs: micro-managers of anticancer combination therapies. Angiogenesis 2017;20(2):269-285.
  62. Van Der Steen N, Potze L, Giovannetti E, Cavazzoni A, Ruijtenbeek R, Rolfo C, Pauwels P, Peters GJ. Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells. Am J Cancer Res 2017;7(4):816-830.
  63. Giovannetti E, van der Borden CL, Frampton AE, Ali A, Firuzi O, Peters GJ. Never let it go: stopping key mechanisms underlying metastasis to fight pancreatic cancer. Semin Cancer Biol. 2017;44:43-59.
  64. Le Large TY, Bijlsma MF, Kazemier G, van Laarhoven HM, Giovannetti E*, Jimenez CR*. Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies. Semin Cancer Biol. 2017;44:153-169 (*equally contributed)
  65. Rovithi M, Avan A, Funel N, Leon LG, Gomez VE, Wurdinger T, Griffioen A, Verheul HM, Giovannetti E. Development of bioluminescent chick chorioallantoic membrane (CAM) models from primary pancreatic cancer cells: a platform for drug testing. Sci Reports 2017;7:44686. doi: 10.1038/srep44686.
  66. Massihnia D, Avan A, Funel N, Maftouh M, van Krieken A, Granchi C, Raktoe R, Boggi U, Aicher B, Minutolo F, Russo A, Leon LG, Peters GJ, Giovannetti E. Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer. J Hematol Oncol 2017;10(1):9
  67. Van Der Steen N, Rolfo C, Pauwels P, Peters GJ, Giovannetti E. Epidermal Growth Factor Receptor tyrosine kinase inhibitors and chemotherapy: a glimmer of hope? J Clin Oncol. 2017;35(6):692-693.
  68. Muller IB, de Langen AJ, Giovannetti E, Peters GJ. Anaplastic Lymphoma Kinase inhibition in metastatic Non-Small Cell Lung Cancer: clinical impact of alectinib. Onco Targets Ther 2017, 10:4535-4541
  69. Santarpia MC, Daffinà MG, D’Aveni A, Marabello G, Liguori A, Giovannetti E, Karachaliou N, Cao MG, Rosell R, Altavilla G. Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy. Drug Des Devel Ther 2017;11:2047-2063
  70. Meijer LL, Frampton AE, Garajová I, Caparello C, Le Large TYS, Funel N, Vasile E, Stebbing J, Krell J, Kazemier G, Giovannetti E. Circulating microRNAs as dynamic biomarkers of response to treatment with FOLFIRINOX combination therapy in advanced pancreatic ductal adenocarcinoma. Lancet 2017;389:S68
  71. Rolfo C, Caglevic C, Santarpia M, Araujo A, Giovannetti E, Gallardo CD, Pauwels P, Mahave M. Immunotherapy in NSCLC: A Promising and Revolutionary Weapon. Adv Exp Med Biol. 2017;995:97-125.
  72. Peters GJ, Muller I, Giovannetti E. Should alectinib or ceritinib be given as first line therapy for ALK positive non-small cell lung cancer patients instead of crizotinib? Transl Cancer Res 2017;6(Suppl 6):S1010-S1013
  73. Palloni A, Mollica V, Ferracin M, Frega F, Maggio I, Giovannetti E, Caparello C, Biasco G, Garajová I. Role of MicroRNA in IPMN Lesions. JOP. Journal of the Pancreas. 2017, Volume 18, Issue S2 (Special Issue: Intraductal Papillary Mucinous Neoplasm), 2017
  74. Caparello C, Vasile E, Garajova I, Ali A, Giovannetti E. Oxaliplatin in pre-treated patients: maybe not the match point? Transl Cancer Res 2017;6(Suppl 1):S163-S167. doi: 10.21037/tcr.2017.01.35
  75. Meijer LL, Puik JR, Peters GJ, Kazemier G, Giovannetti E. hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients. Oncologist. 2016;21(12):e4.
  76. Van Der Steen N, Caparello C, Rolfo C, Pauwels P, Peters GJ, Giovannetti E. New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong? Onco Targets Ther 2016;9:6065-6074.
  77. Mato Prado M, Frampton AE, Giovannetti E, Stebbing J, Castellano L, Krell J. Investigating miRNA-mRNA regulatory networks using crosslinking immunoprecipitation methods for biomarker and target discovery in cancer. Expert Rev Mol Diagn. 2016;27:1-8.
  78. Caparello C, Meijer LL, Garajova I, Falcone A, Le Large TY, Funel N, Kazemier G, Peters GJ, Vasile E, Giovannetti E. FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. World J Gastroenterol 2016;22:6987-7005
  79. Van Der Steen N, Giovannetti E, Pauwels P, Peters GJ, Hong DS, Cappuzzo F, Hirsch FR, Rolfo C. cMET exon 14 skipping: from the structure to the clinic. J Thorac Oncol 2016;11:1423-1432
  80. Leon LG, Funel N, Peters GJ, Avan A, Vistoli F, Boggi U, Giovannetti E. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy. Clin Cancer Res 2016;22:2594
  81. Le Large TY, Mato Prado M, Krell J, Bijlsma MF, Meijer LL, Kazemier G, Frampton AE, Giovannetti E. Bioinformatic analysis reveals pancreatic cancer molecular subtypes specific to the tumor and the microenvironment. Expert Rev Mol Diagn 2016;16:733-736
  82. Frampton AE, Krell J, Mato Prado M, Gall TMH, Abbassi-Ghadi N, Del Vecchio Blanco G, Funel N, Giovannetti E, Castellano L. Habib NA, Vlavianos P, Stebbing J, Jiao LR. Prospective Validation of microRNA Signatures for Detecting Pancreatic Malignant Transformation in Endoscopic-Ultrasound Guided Fine-Needle Aspiration Biopsies. Oncotarget 2016;7:28556-28569
  83. Ciccolini J, Serdjebi C; Peters GJ, Giovannetti E. Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: a PAMM-EORTC perspective. Cancer Chem Pharmacol 2016;78:1-12
  84. Passiglia F, Caparica R, Giovannetti E, Giallombardo M, Listi A, Diana P, Cirrincione G, Caglevic C, Raez LE, Russo A, Rolfo C. The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer. Exp Opin Invest New Drugs 2016;25:385-392
  85. Klionsky DA, […], Giovannetti E, et al. (including more than other 100 coauthors, in alphabetic order) Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 2016;12:1-222
  86. Verbrugge SE, Al M, Assaraf YG, Kammerer S, Chandrupatla DMSH, Honeywell R, Musters RPJ, Giovannetti E, O’Toole T, Scheffer GL, Krige DG, de Gruijl TD, Niessen HWM, Lems WF, Kramer PA, Scheper RJ, Cloos J, Ossenkoppele GJ, Peters GJ, Jansen G. Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation of ERK/Akt/mTOR. Oncotarget 2016;7:5240-5257
  87. Giovannetti E, Zucali PA, Rolfo C, Assaraf YG, Peters GJ. Prognostic and predictive role of thymidylate synthase expression in lung cancer: the debate is still open. J Clin Oncol 2016;34:511-512
  88. Sciarrillo R, Wojtuszkiewicz A, Kooi IE, Gómez VE, Boggi U, Jansen G, Kaspers GJ, Cloos J, Giovannetti E. Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models. J Vis Exp. 2016(118)
  89. Van Der Steen N, Deben C, Deschoolmeester V, Wouters A, Lardon F, Rolfo C, Germonpré P, Giovannetti E, Peters GJ, Pauwels P. Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer. World J Clin Oncol. 2016;7(6):425-432
  90. Giovannetti E, Leon LG, Gómez VE, Zucali PA, Minutolo F, Peters GJ. A specific inhibitor of lactate dehydrogenase overca the resistance towards gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1. Nucleosides Nucleotides Nucleic Acids. 2016;35(10-12):643-651
  91. Avan A, Narayan R, Giovannetti E, Peters GJ. Role of Akt signaling in resistance to DNA-targeted therapy. World J Clin Oncol. 2016;7(5):352-369
  92. Van Der Steen N, Rolfo C, Giovannetti E, Reclusa P, Peters GJ, Pauwels P (2016) cMET in NSCLC: Expression, Amplification and Mutations. Track: Biology and Pathogenesis. J Thorac Oncol 11(10S):S221-S222
  93. Santarpia M, Giovannetti E, Rolfo C, Karachaliou N, González-Cao M, Altavilla G, Rosell R. Recent developments in the use of immunotherapy in non-small cell lung cancer. Expert Rev Respir Med 2016;10:781-788
  94. Santarpia M, Karachaliou N, González-Cao M, Altavilla G, Giovannetti E, Rosell R. Feasibility of cell-free circulating tumor DNA testing for lung cancer. Biomark Med 2016;10:417-430
  95. Santarpia MC, Rolfo C, Peters GJ, Leon LG, Giovannetti E. On the pharmacogenetics of non-small cell lung cancer treatment. Expert Opin Drug Metab Toxicol 2016;12:307-317
  96. Muller IB, de Langen AJ, Honeywell RH, Giovannetti E, Peters GJ. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib. Exp Rev Anticancer Ther 2016;16:147-157
  97. Honeywell RJ, Avan A, Giovannetti E, Peters GJ. Tissue distribution of crizotinib and gemcitabine combination in a patient-derived orthotopic mouse model of pancreatic cancer. ADMET & DMPK 2016 (4); doi: 10.5599/admet.4.4.335
  98. Garajová I, Le Large TY, Giovannetti E, Kazemier G, Biasco G, Peters GJ. The Role of MicroRNAs in Resistance to Current Pancreatic Cancer Treatment: Translational Studies and Basic Protocols for Extraction and PCR Analysis. Methods Mol Biol. 2016;1395:163-87.
  99. Garajová I, Funel N, Fiorentino M, Agostini V, Ferracin M, Negrini M, Frassineti GL, Gavelli G, Frampton AE, Biasco G, Giovannetti E. MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma – a step towards personalized therapy. Clin Epigenetics 2015;7:129
  100. Le Large TYS, Meijer LL, Mato Prado M, Kazemier G, Frampton AE, Giovannetti E. Circulating microRNAs as diagnostic biomarkers for pancreatic cancer. Exp Rev Mol Diagn 2015;15:1525-1529
  101. Rolfo C, Ruiz R, Giovannetti E, Gil-Bazo I, Peeters M, Raez L. Entrectinib: A potent new TRK, ROS1, and ALK inhibitor–a therapeutic opportunity not only for Non-Small Cell Lung Cancer. Exp Opin Invest New Drugs 2015;24:1493-1500
  102. De Mattos-Arruda L Bottai G, Nuciforo PG, Di Tommaso L, Giovannetti E, Peg V, Losurdo A, Pérez-Garcia J, Masci G, Corsi F, Cortés J, Seoane J, Calin GA, Santarpia L. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget 2015;6:37269-37280.
  103. Gomez Mellado V, Giovannetti E, Peters GJ. Unraveling the complexity of autophagy: potential therapeutic applications in Pancreatic Ductal Adenocarcinoma. Sem Cancer Biol 2015;35:11-19
  104. Frampton AE, Castellano L, Colombo T, Giovannetti E, Krell J, Jacob J, Pellegrino L, Roca-Alonso L, Funel N, Gall TM, Ahmad R, Habib NA, Knösel T, Stebbing J, Jiao LR. Integrated molecular analysis to investigate the role of microRNAs in pancreatic tumour growth and progression. Lancet 2015;385:S1-37
  105. van Zweeden AA, van der Vliet HJ, Wilmink JW, Meijerink MR, Meijer OWM, Bruynzeel AME, van Tienhoven G, Giovannetti E, Kazemier G, Jacobs MAJM, Verheul HMW. Phase I clinical trial to determine the feasibility and maximum tolerated dose of panitumumab to standard gemcitabine-based chemoradiation in locally advanced pancreatic cancer. Clin Cancer Res 2015;21:4569-4575
  106. Galvani E, Sun J, Leon LG, Sciarrillo R, Narayan RS, Sjin RTT, Lee K, Ohashi K, Heideman DAM, Alfieri RR, Heynen GJ, Bernards R, Smit EF, Pao W, Peters GJ, Giovannetti E. NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor. Oncotarget 2015;6:42717-42732
  107. Frampton AE, Krell J, Jamieson NB, Gall TMH, Giovannetti E, Funel N, Mato Prado M, Krell D, Habib NA, Castellano L, Jiao LR, Stebbing J. microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: a meta-analysis. Eur J Cancer 2015;51:1389-1404
  108. Le Large TYS, Frampton AE, Meijer L, Stebbing J, Kazemier G, Giovannetti E. Usefulness of measuring microRNAs in bile and plasma for pancreatic ductal adenocarcinoma (PDAC) diagnosis. Am J Gastroenterol 2015;110:768-769
  109. Avan A, Postma TJ, Ceresa C, Avan A, Cavaletti G, Giovannetti E, Peters GJ. Platinum-Induced Neurotoxicity and Preventive Strategies: Past, Present, and Future. Oncologist 2015;20:411-432
  110. Vasile E, Tibaldi C, D’Incecco A, Leon LG, Giovannetti. Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of Docetaxel in Non-Small-Cell Lung Cancer (NSCLC) Patients. J Cancer Res Clin Oncol. 2015;141:1189-1194
  111. Garajová I, Giovannetti E Biasco G, Peters GJ. C-Met as a target for personalized therapy. Transl Oncogenomics 2015;Suppl.1:13-31
  112. Gandellini P, Giovannetti E, Nicassio F. MicroRNAs in Cancer Management: Big Challenges for Small Molecules. BioMed Research International 2015:982156
  113. MiRNAs and Their Interference with the Main Molecular 
Mechanisms Responsible for Drug Resistance in Pancreatic 
Cancer. Garajova I, Giovannetti E, Caponi S, van Zweeden A, Peters GJ. Curr Pharmacol Reports 2015;1:4:223-32.
  114. Porcelli L, Giovannetti E, Jansen G, Assaraf YG, Scheffer GL, Kathman I, Azzariti A, Paradiso A, Peters GJ. The EGFR pathway regulates BCRP expression in NSCLC cells: role of Erlotinib. Curr Drug Targets 2014;15:1322-1330.
  115. Leon LG, Gemelli M, Avan A, Zucali PA, Funel N, Santoro A, Giovannetti E. Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells. Curr Drug Targets. 2014;15:1331-40
  116. Giovannetti E, Leon LG. New Strategies And Applications For Drugs Targeting EGFR and C-Met. Curr Drug Targets. 2014;15:1261-1262
  117. Sissung TM, Price DK, Del Re M, Ley AM, Giovannetti E, Figg WD, Danesi R. Genetic variation: Effect on prostate cancer. Biochim Biophys Acta 2014;1846:446-456
  118. Avan A, Avan A, Le Large TYS, Mambrini A, Funel N, Maftouh M, Ghayour-Mobarhan M, Cantore M, Boggi U, Peters GJ, Pacetti P, Giovannetti E. AKT1 and SELP polymorphisms predict the risk of developing cachexia in pancreatic cancer patients. PLoS ONE 2014;9:e108057
  119.  Avan A, Avan A, Giovannetti E, Peters GJ. Calcium/magnesium infusion for oxaliplatin-induced neuropathy: protective or not? J Clin Oncol 2014;32:3341
  120. Robert J, Valérie Le Morvan V, Giovannetti E, Peters GJ. On the use of pharmacogenetics in cancer treatment and clinical trials. Eur J Cancer 2014;50:2532-2543.
  121. Maftouh M, Belo AI, Avan A, Funel N, Peters GJ, Giovannetti E,* van Die I*. Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/β-catenin signalling in pancreatic adenocarcinoma. Oncotarget 2014;5:5335-5349 (*equally contributed)
  122. Rolfo C, Giovannetti E, Hong DS, Bivona T, Raez L, Bronte G, Buffoni L, Reguart N, Santos E, Germonpré P, Taron M, Passiglia F, Van Meerbeeck JP, Russo A, Peeters M, Bazo IG, Pauwels P, Rosell R. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. Cancer Treat Rev 2014;40:990-1004
  123. Avan A, Maftouh M, Avan A, Tibaldi C, Zucali PA, Giovannetti E. SNPs in PI3K–PTEN–mTOR and Brain Metastases in NSCLC – Letter. Clin Cancer Res 2014;20:3623-3624
  124. Maftouh M, Avan A, Funel N, Paolicchi E, Vasile E, Pacetti P, Vaccaro V, Faviana P, Campani D, Caponi S, Mambrini A, Boggi U, Cantore M, Milella M, Peters GJ, Reni M, Giovannetti E. A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients. Pharmacogenomics 2014;15:609-618
  125. Frampton AE, Giovannetti E, Jamieson NB, Krell J, Gall TM, Stebbing J, Jiao LR, Castellano L. A microRNA meta-signature for pancreatic ductal adenocarcinoma. Expert Rev Mol Diagn 2014;14:267-271
  126. Giovannetti E, Giaccone G. CYB5A and autophagy-mediated cell death in pancreatic cancer. Autophagy 2014;1094:697-8
  127. Giovannetti E, Wang Q, Avan A, Funel N, Lagerweij T, Lee JH, Caretti V, van der Velde A, Boggi U, Wang Y, Vasile E, Peters GJ, Wurdinger T, Giaccone G. CYB5A role in pancreatic cancer prognosis and autophagy modulation (2104) JNCI – J Natl Cancer Inst. 2014;106:djt346
  128. Frampton AE,* Castellano L,* Colombo T, Giovannetti E, Krell J, Jacob J, Pellegrino L, Roca-Alonso L, Funel N, Gall TMH, Di Giorgio A, Fulci V, Britton DJ, Ahmad R, Habib NH, Knösel T, Coombes TC, Stebbing J, Jiao LR. miRNAs Co-operatively Inhibit a Network of Tumor Suppressor Genes to Promote Pancreatic Tumor Growth and Progression. Gastroenterology 2014;146:268-277 (*equally contributed)
  129. Maftouh M, Avan A, Sciarrillo R, Granchi C, Leon LG, Rani R, Funel N, Smid K, Honeywell R, Boggi U, Minutolo F, Peters GJ, Giovannetti E. Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia. Br J Cancer 2014;110:172-182
  130. Galvani E, Toffalorio F, Peters GJ, Pas TD, Giovannetti E. Clinical application of pharmacogenetics of non-small cell lung cancer (NSCLC): time to “work it out”? Curr Pharm Des 2014;20:3863-3874
  131. Avan A, Maftouh M, Funel N, Ghayour-Mobarhan M, Boggi U, Peters GJ, Giovannetti E. MET as a potential therapeutic target for the treatment of upper gastrointestinal cancers: characterization of novel c-Met inhibitors for therapeutic intervention. Curr Med Chem 2014;21:975-89
  132. Bronte G, Rolfo C, Giovannetti E, Cicero G, Pauwels P, Passiglia F, Castiglia M, Rizzo S, Lo Vullo F, Fiorentino E, Van Meerbeeck J, Russo A. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. Crit Rev Hematol Oncol 2014;89:300-313
  133. Garajova I, Le Large TYS, Frampton AE, Rolfo C, Voortman J, Giovannetti E (2014) Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer. BioMed Research International 2014:678401
  134. Rolfo C, Fanale D, Hong DS, Tsimberidou AM, Piha-Paul SA, Pauwels P, Van Meerbeeck JP, Caruso S, Bazan V, Cicero G, Russo A, Giovannetti E. Impact of MicroRNAs in Resistance to Chemotherapy and Novel Targeted Agents in Non-Small Cell Lung Cancer. Curr Pharm Biotechnol. 2014;15:475-485
  135. Maftouh M, Avan A, Funel N, Frampton AE, Fiuji H, Pelliccioni S, Castellano L, Galla’ V, Peters GJ, Giovannetti E. MiR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behaviour of pancreatic cancer cells. Nucleosides Nucleotides Nucleic Acids 2014;33:384-393
  136. Peters GJ, Honeywell RJ, Maulandi M, Giovannetti E, Losekoot N, Etienne-Grimaldi MC, Milano G, Serdjebi C, Ciccolini J; for the EORTC-Pharmacology and Molecular Mechanism Group. Selection of the Best Blood Compartment to Measure Cytidine Deaminase Activity to Stratify for Optimal Gemcitabine or Cytarabine Treatment. Nucleosides Nucleotides Nucleic Acids 2014;33:403-412
  137. Characterization of and Protection from Neurotoxicity Induced by Oxaliplatin, Bortezomib and Epothilone-B. Ceresa C, Avan A, Giovannetti E, Geldof AA, Avan A, Cavaletti G, Peters GJ. Anticancer Res 2014;34:517-523
  138. Peters GJ, Avan A, Gallegos Ruiz M, Avan A, Orsini V, Giovannetti E, Smit EF. Predictive role of repair enzymes in the efficacy of cisplatin combinations in pancreatic and lung cancers. Anticancer Res 2014;34:435-442
  139. Sciarrillo R, Minutolo F, Peters GJ, Giovannetti E. Lactate dehydrogenase acetylation adds another piece to the puzzle of metabolic reprogramming in pancreatic cancer. Transl Gastrointest Cancer 2014;3:64-66.
  140. La Monica S, Caffarra C, Saccani F, Galvani E, Galetti M, Fumarola C, Bonelli M, Cavazzoni A, Cretella D, Sirangelo R, Tiseo M, Ardizzoni A, Giovannetti E§, Petronini PG, Alfieri RR. Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification. PLoS ONE 2013;8:e78656 (§co-corresponding author)
  141.  Avan A, Caretti V, Funel N, Galvani E, Maftouh M, Honeywell RJ, Lagerweij T, Van Tellingen O, Campani D, Fuchs D, Verheul HM, Schuurhuis GJ, Boggi U, Peters GJ, Würdinger T, Giovannetti E. Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma. Cancer Res 2013;73:6745-6756
  142. García-Santisteban I, Peters GJ, Giovannetti E, Rodríguez JA.USP1 deubiquitinase: cellular functions, regulatory mechanisms and emerging potential as target in cancer therapy. Mol Cancer 2013;12:91
  143. Frampton AE, Krell J, Kazemier G, Giovannetti E. Serum miR-1290 as a marker of pancreatic cancer – Letter. Clin Cancer Res 2013;19:5250-5251
  144. Giovannetti E, Peters GJ, Zucali PA. One marker does not fit all: additional translational and validation studies are needed to identify faithful predictors of pemetrexed activity in mesothelioma. J Thor Oncol 2013;8:e79-80
  145. Frings V, Van der Veldt AAM, Boellaard R, Herder GJM, Giovannetti E, Honeywell R, Peters GJ, Thunnissen E, Hoekstra OS, Smit EF. Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography. PLoS ONE 2013;8:e63705
  146. Ciccolini J, Peters GJ, Giovannetti E. Gender, Cytidine Deaminase, and 5-Aza/Decitabine–Letter. Clin Cancer Res 2013;19:3105
  147. Frampton AE, Gall TM, Giovannetti E, Stebbing J, Castellano L, Jiao LR, Krell J. Distinct miRNA profiles are associated with malignant transformation of pancreatic cystic tumors revealing potential biomarkers for clinical use. Expert Rev Mol Diagn 2013;13:325-329
  148. Avan A, Maftouh M, Giovannetti E. An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: Implications for adjuvant treatment. Cancer 2013;119:2662-2663
  149. Azijli K, Yuvaraj S, van Roosmalen I, Flach K, Giovannetti E, Peters GJ, de Jong S, Kruyt FAE. MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC cells that involves RIP1 and caspase-8 and is mediated by Mcl-1. Apoptosis 2013;18(7):851-860
  150. Avan A, Pacetti P, Reni M, Milella M, Vasile E, Mambrini A, Vaccaro V, Caponi S, Cereda S, Peters GJ, Cantore M, Giovannetti E. Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back. Int J Cancer 2013;133:1016-1022
  151. Galvani E,* Giovannetti E,* Saccani F, Cavazzoni A, Leon LG, Dekker H, Alfieri R, Carmi C, Mor M, Ardizzoni A, Petronini PG, Peters GJ. Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in Non-Small Cell Lung Cancer. Neoplasia 2013;15:61-72 (*equally contributed)
  152. Pistilli B, Bellettini G, Giovannetti E, Codacci-Pisanelli G, Azim HA Jr., Sarno MA, Peccatori FA. Chemotherapy, targeted agents, antiemetics and growth-factors in human milk: how should we counsel cancer patients about breastfeeding? Cancer Treat Rev 2013;39:207-211
  153. Caponi S, Funel N, Frampton AE, Mosca F, Santarpia L, Van der Velde A, Jiao LR, De Lio N, Falcone A, Kazemier G, Mejer GA, Verheul HM, Vasile E, Peters GJ, Boggi U, Giovannetti E. The Good, the Bad and the Ugly: a Tale of MiR-101, MiR-21 and MiR-155 in Pancreatic Intraductal Papillary Mucinous Neoplasms. Ann Oncol 2013;24:734-741
  154. Avan A, Quint K, Nicolini F, Funel N, Frampton AE, Maftouh M, Pelliccioni S, Schuurhuis GJ, Peters GJ, Giovannetti E. Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer. Curr Pharm Design 2013;19:940-950
  155. Giovannetti E, Labots M, Dekker H, Galvani E, Lind JSW, Sciarrillo R, Honeywell R, Smit EF, Verheul HM, Peters GJ. Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells. Curr Pharm Design 2013;19:927-939
  156. Galvani E, Alfieri R, Giovannetti E, Cavazzoni A, La Monica S, Galetti M, Fumarola C, Bonelli M, Mor M, Tiseo M, Peters GJ, Petronini PG, Ardizzoni A. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: current status and future perspective in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer. Curr Pharm Design 2013;19:818-832
  157. Giovannetti E, Peters GJ. Development of new molecular agents targeting key signalling pathways activated by growth factors in human cancer. Curr Pharm Design 2013;19:807
  158. Paolicchi E, Pacetti P, Giovannetti E, Mambrini A, Orlandi M, Crea F, Romani AA, Tartarini R, Danesi R, Peters GJ, Cantore M. A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma. Oncol Lett 2013;6:1487-1491.
  159. Maftouh M, Avan A, Galvani E, Peters GJ, Giovannetti E. Molecular mechanisms underlying the role of microRNAs in resistance to Epidermal Growth Factor Receptor-targeted agents and novel therapeutic strategies for treatment of Non-Small-Cell Lung Cancer. Crit Rev Oncogenesis 2013;18:317-26. (5th Most Downloaded Article of this journal in the year 2013-2104:
  160. Barcelos A, Giovannetti E,° de Jonge R, Maftooh M, Griffioen P, Hanauske AR, Peters GJ. Polymorphisms Correlated with the Clinical Outcome of Locally Advanced or Metastatic Colorectal Cancer Patients Treated with ALIRI vs FOLFIRI. Pteridines 2013;24:69-79 (°Corresponding author)
  161. Peters GJ, Galvani E, Jansen G, Assaraf Y, Giovannetti E. Thymidylate synthase inhibitors for thoracic tumors. Pteridines 2013;24:57-67
  162. Frampton AE, Krell J, Giovannetti E, Jiao LR, Stebbing J. Role of miRNAs in the response to anticancer therapy. Pharmacogenomics 2012;13:1663-1666
  163. Giovannetti E, Van der Velde AG, Funel N, Vasile E, Perrone V, Leon LG, De Lio N, Avan A, Caponi S, Pollina LE, Gallá V, Sudo H, Falcone A, Campani D, Boggi U, Peters GJ. High-throughput microRNA (miRNAs) arrays unravel the prognostic role of miR-211 in pancreatic cancer. PLoS ONE 2012;7:e49145
  164. Peters GJ, Giovannetti E. Research Highlights: Highlights from the latest articles in pharmacogenomics of irinotecan/cisplatin toxicity. Pharmacogenomics 2012;13:1445-1447
  165. Erdem L,* Giovannetti E,* Leon LG, Honeywell R, Peters GJ. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib. Curr Top Med Chem 2012;12(15):1649-1659 (*these authors equally contributed to the study)
  166. Tiseo M*, Giovannetti E*, Tibaldi C*, Camerini A, Di Costanzo F, Barbieri F, Burgers JA, Vincent A, Peters GJ, Smit EF, Ardizzoni A. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. Lung Cancer 2012;78:92-99 (*these authors equally contributed to the study)
  167. Galvani E, Peters GJ, Giovannetti E (2012) EGFR-targeted therapy in NSCLC: role of germline polymorphisms in outcome and toxicity. Future Oncol 8:1015-1029
  168. Giovannetti E, Toffalorio F, De Pas T, Peters GJ. Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer (NSCLC): a changing landscape? Pharmacogenomics 2012;13:1073-1086
  169. Avan A, Crea F, Paolicchi E, Funel N, Galvani E, Marquez VE, Honeywell RJ, Danesi R, Peters GJ, Giovannetti E. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A (DZNeP) with gemcitabine in pancreatic cancer cells. Mol Cancer Ther 2012;11:1735-1746; selected in the Highlights of the issue
  170. Giovannetti E, Codacci-Pisanelli G, Peters GJ. Methylation status of TFAP2E and chemoresistance in colorectal cancer. New Engl J Med 2012;366:966
  171. Elnaggar M, Giovannetti E, Peters GJ. Molecular targets of gemcitabine action: rationale for development of novel drugs and drug combinations. Curr Pharm Design 2012;18:2811-2829
  172. Giovannetti E, Erozenci A, Smit J, Danesi R, Peters GJ. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Hematol Oncol 2012;81:103-122 (#10 among the most 25 downloaded articles in Crit Rev Hematol Oncol from January to February 2011)
  173. Peccatori FA, Giovannetti E, Pistilli B, Bellettini G, Codacci-Pisanelli G, Losekoot N, Curigliano G, Azim HA Jr, Goldhirsh A, Peters GJ. The only thing I know is that I know nothing: 5-FU in human milk. Ann Oncol 2012;23:543-544
  174. Lee JH, Giovannetti E, Hwang JH, Petrini I, Wang Q, Voortman J, Wang Y, Steinberg SM, Funel N, Meltzer P, Wang Y, Giaccone G. Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer. Clin Cancer Res 2012;18:524-533
  175. Tibaldi C,* Giovannetti E,* Tiseo M,* Leon LG, D’Incecco A, Losekoot N, Bartolotti M, Honeywell R, Cappuzzo F, Ardizzoni A, Peters GJ. Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine/platinum-treated advanced Non-Small-Cell lung cancer patients. Ann Oncol 2012;23:670-677 (*these authors equally contributed to the study)
  176. Frampton AE, Krell J, Giovannetti E, Krell D, Stebbing J, Castellano L, Jiao LR. Defining a prognostic molecular profile for ductal adenocarcinoma of the pancreas highlights known key signaling pathways. Expert Rev Anticancer Ther. 2012;12:1275-1278
  177. Giovannetti E,* Pacetti P,*  Reni M,* Leon GL, Mambrini A, Vasile E, Ghidini M, Funel N, Lucchesi M, Cereda S, Peters GJ, Cantore M. Association between DNA repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics 2011;12(12):1641-1652 (*these authors equally contributed to the study)
  178. Giovannetti E, Zucali PA, Assaraf YG, Leon LG, Smid K, Alecci C, Giancola F, Destro A, Gianoncelli L, Lorenzi E, Roncalli M, Santoro A, Peters GJ. Preclinical emergence of vandetanib as a potent antitumor agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. Br J Cancer 2011;105:1542-1553
  179. Granchi C, Roy S, De Simone A, Salvetti I, Tuccinardi T, Martinelli A, Macchia M, Lanza M, Betti L, Giannaccini G, Lucacchini A, Giovannetti E, Sciarrillo R, Peters GJ, Minutolo F. N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation. Eur J Med Chem 2011;46:5398-5407
  180. Galvani E, Peters GJ, Giovannetti E. Thymidylate synthase inhibitors for non-small cell lung cancer. Exp Opin Invest Drugs 2011;20(10):1343-1356
  181. Funel N,* Giovannetti E,* Pollina LE, Del Chiaro M, Mosca F, Boggi U, Campani D. Critical role of laser microdissection for genetic, epigenetic and proteomic analyses in pancreatic cancer. Exp Rev Mol Diagn 2011;11(7):695-701 (*these authors equally contributed to the study)
  182. León LG,* Giovannetti E,* Smid K, Hanauske AR, Giaccone G, Peters GJ. DNA copy number profiles correlate with outcome in colorectal cancer patients treated with fluoropyrimidine/antifolate-based regimens. Curr Drug Metab 2011;12:956-965. (*equally contributed)
  183. Granchi C, Roy S, Macchia M, Tuccinardi T, Martinelli A, Lanza M, Betti L, Giannaccini G, Lucacchini A, Funel N, León LG, Giovannetti E, Peters GJ, Palchaudhuri R, Hergenrother PJ, Minutolo F. Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against tumors. J Med Chem 2011;54(6):1599-1612
  184. De Pas T, Toffalorio F, Giovannetti E, Radice D, Russo F, Angeli I, Calamai G, Spitaleri G, Catania C, Noberasco C, Milani A, Pelosi G, Danesi R, de Braud F. Optimizing pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer: a pharmacogenetic approach. J Thorac Oncol 2011;6:768-773 (°Corresponding author)
  185. Funel N, Morelli M, Giovannetti E,° Del Chiaro M, Polina LE, Mosca F, Boggi U, Cavazzana A, Campani D. Loss of Heterozygosity (LOH) status of D9S105 marker is associated with down-regulation of Kruppel-Like Factor 4 (KLF4) expression in Pancreatic Ductal Adenocarcinoma and PanINs. Pancreatology 2011;11:30-42 (°Corresponding author)
  186. Lemos C,* Giovannetti E,* Zucali PA, Assaraf YG, Scheffer GL, van der Straaten T, D’Incecco A, Falcone A, Santoro A, Giaccone G, Tibaldi C, Peters GJ. The impact of ABCG2 polymorphisms on clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. Pharmacogenomics 2011;12:159-170 (*equally contributed)
  187. Zucali PA, Giovannetti E, Destro A, Ceresoli GL, Gianoncelli L, Lorenzi E, De Vincenzo F, Simonelli M, Thunissen E, Giordano L, Roncalli M, Peters GJ, Santoro A. Thymidylate Synthase (TS) and Excision Repair Cross-Complementing Group-1 (ERCC-1) as predictors of response in malignant pleural mesothelioma patients treated with pemetrexed and carboplatin. Clin Cancer Res 2011;17:2581-2590
  188. Tibaldi C*, Giovannetti E*, Vasile E, Boldrini L, Gallegos-Ruiz MI, Bernardini I, Incensati R, Danesi R, Cappuzzo F, Peters GJ, Fontanini G. Inherited germ-line T790M mutations and somatic EGFR- mutations in Non-Small Cell Lung cancer patients. (*these authors equally contributed to the study) J Thorac Oncol 2011;6:395-396
  189. Funel N, Vasile E, Del Chiaro M, Boggi U, Falcone A, Campani D, Scarpa A, Giovannetti E. Correlation of basal EGFR expression with pancreatic cancer grading but not with clinical outcome after gemcitabine-based treatment. Ann Oncol 2011;22(2):482-484
  190. Giovannetti E, Erdem L, Olcay E, Leon LG, Peters GJ. Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer. Front Bioscience 2011;16:116-130 (*these authors equally contributed to the study)
  191. Hodzic J, Giovannetti E, Calvo BD, Adema AD, Peters GJ. Regulation of Deoxycytidine Kinase Expression and Sensitivity to Gemcitabine by Micro-RNA 330 and Promoter Methylation in Cancer Cells. Nucleosides Nucleotides Nucleic Acids 2011;30:1214-1222
  192. Honeywell RJ, Giovannetti E, Peters GJ. Determination of the Phosphorylated Metabolites of Gemcitabine and of Difluorodeoxyuridine by LC/MS-MS. Nucleosides Nucleotides Nucleic Acids 2011;30:1203-1213
  193. Broekman F, Giovannetti E, Peters GJ. Tyrosine kinase inhibitors: multi-targeted or single-targeted? World J Clin Oncol 2011;2:80-93
  194. Bijnsdorp IV, Giovannetti E, Peters GJ. Analysis of drug interactions. Methods Mol Biol 2011;731:421-434
  195. Pastina I*, Giovannetti E*, Chioni A, Sissung TM, Crea F, Orlandini C, Price DK, Cianci C, Figg WD, Ricci S, Danesi R. Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Hormone Refractory Prostate Cancer (HRPC) patients. BMC Cancer 2010;10:511 (*these authors equally contributed to the study)
  196. Toffalorio F, De Pas T, Giovannetti E (2010) Differences of Gene Expression in Non-Small Cell Lung Cancer: Are Histology, Tumor Site, and Methodology Relevant? J Thorac Oncol 2010;5:1310-1311
  197. Hwang JH,* Voortman V,* Giovannetti E,* Steinberg SM, Leon LG, Kim YT, Funel N, Park JK, Kim MA, Kang GH, Kim SW, Del Chiaro M, Peters GJ, Giaccone G. MicroRNA-21 as a biomarker for benefit from adjuvant therapy in resectable pancreatic adenocarcinoma. PLoS ONE 2010;5:e10630 (*these authors equally contributed to the study)
  198. Giovannetti E, Funel N, Peters GJ, Del Chiaro M, Erozenci LA, Leon GL, Groen A, Pollina LE, Danesi R, Campani D, Verheul HM, Boggi U. MicroRNA-21 (miR-21) in pancreatic adenocarcinoma (PDAC): correlation with clinical outcome and pharmacological aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 2010;70:4528-4538
  199. Zucali PA,* Giovannetti E,* Assaraf YG, Ceresoli GL, Peters GJ, Santoro A. New tricks for old biomarkers: thymidylate synthase expression as a predictor of pemetrexed activity in mesothelioma. Ann Oncol 2010; 21:1560-1561 (*these authors equally contributed to the study)
  200. Lind JSW, Dingemans AMC, Groen HJM, Thunnissen FB, Bekers O, Heideman D, Honeywell R, Giovannetti E, Postmus P, Smit EF. A multicenter, phase II study of erlotinib and sorafenib in chemotherapy naïve patients with advanced non-small cell lung cancer. Clin Cancer Res 2010;16(11):3078-3087
  201. Honeywell R, Yarzadah K, Giovannetti E, Losekoot N, Smit EF, Tibaldi C, Walraven M, Lind J, Verheul HM, Peters GJ. A simple and selective method for determination of several tyrosine kinase inhibitors by liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:1059-1068
  202. Giovannetti E, Tibaldi C, Falcone A, Danesi R, Peters GJ. Impact of Cytidine Deaminase Polymorphisms on Toxicity after Gemcitabine: The Question Is Still Ongoing. J Clin Oncol 2010;28:e221-222
  203. Giovannetti E, Zucali P, Peters GJ, Cortesi F, D’Incecco A, Smit EF, Falcone A, Burgers S, Santoro A, Danesi R, Giaccone G, Tibaldi C. Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small-cell lung cancer patients treated with gefitinib. Mol Cancer Ther2010; 9:581-593; selected in the Highlights of the issue
  204. Nannizzi S, Veal GJ, Giovannetti E°, Mey V, Ricciardi S, Del Tacca M, Danesi R. Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cells. Cancer Chemother Pharmacol 2010; 66:547-558 (°Corresponding author)
  205. Toffalorio F*, Giovannetti E*, De Pas T, Danesi R, Radice D, Pelosi G, Manzotti M, Minocci D, Spaggiari L, Spitaleri G, Noberasco C, Catania C, Boselli S, De Braud F. Expression of gemcitabine and cisplatin-related genes in NSCLC. Pharmacogenomics J 2010;10:180-190 (*these authors equally contributed to the study)
  206. Giovannetti E, Honeywell R, Hanauske AR, Tekle C, Kuenen B, Sigmond J, Lahn M, Giaccone G, Peters GJ. Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer. Curr Drug Targets 2010;11:12-28
  207. Peters GJ, Hodzic J, Ortega B, Giovannetti E, Adema AD, Broekhuizen R, Kaspers GJ, Hubeek I (2010) Promoter methylation of deoxycytidine kinase in cancer cells. Nucleosides Nucleotides Nucleic Acids 2010;29:408-413
  208. Giovannetti E, Leon GL, Bertini S, Macchia M, Minutolo F, Funel N, Alecci C, Giancola F, Danesi R, Peters GJ. Study of apoptosis induction and deoxycytidine kinase/cytidine deaminase modulation in the synergistic interaction of a novel ceramide analog and gemcitabine in pancreatic cancer cells. Nucleosides Nucleotides Nucleic Acids 2010;29:419-426
  209. Olcay E, Giovannetti E, Peters GJ. Drug Delivery and Drug Resistance:  EGFR-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. The Open Lung Cancer Journal 2010; 3:26-33
  210. Peters GJ, Honeywell RH, Leon LG, van Groeningen CJ, Jansen G, Ylstra B, Meijer GA, Giovannetti E. Role of Pharmacodynamics, Pharmacogenetic and Pharmacogenomics Biomarkers of Cancer Chemotherapy with Antifolates. Pteridines 2010, 20:115-27
  211. Mauritz R, Giovannetti E, Beumer IJ, van Groeningen CJ, Pinedo HM, Peters GJ (2009) Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of colorectal cancer patients. Clin Colorectal Cancer 2009;8:146-154
  212. Crea F, Giovannetti E, Cortesi F, Mey V, Nannizzi S, Gallegos-Ruiz M, Ricciardi S, Del Tacca M, Peters GJ, Danesi R (2009) Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cells. Mol Cancer Ther 8:1964-1973.
  213. Ceresa C*, Giovannetti E*, Voortman J, Laan AC, Honeywell R, Giaccone G, Peters GJ (2009) Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer (NSCLC) and peripheral blood mononuclear cells (PBMCs). Mol Cancer Ther 8:1026-1032 (*these authors equally contributed to the study)
  214. Danesi R, Pasqualetti G, Giovannetti E, Crea F, Altavilla G, Del Tacca M, Rosell R. Pharmacogenomics in non-small-cell lung cancer chemotherapy. Adv Drug Deliv Rev 2009;61:408-417
  215. Lemos C, Kathmann I, Giovannetti E, Beliën JAM, Scheffer GL, Calhau C, Jansen G, Peters GJ (2009) Cellular folate status modulates the expression of BCRP and MRP multidrug transporters in cancer cell lines from different origins. Mol Cancer Ther 8:655-664
  216. Danesi R, Altavilla G, Giovannetti E, Rosell R (2009) Pharmacogenomics of gemcitabine in non-small cell lung cancer (NSCLC) and other solid tumors. Pharmacogenomics 10:69-80.
  217. Lemos C, Ietje Kathmann I, Giovannetti E, Calhau C, Jansen G, Peters GJ (2009) Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib. Br J Cancer 100:1120-1127
  218. Crea F*, Giovannetti E*, Zinzani PL, Danesi R (2009) Pharmacological rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization. Crit Rev Hematol Oncol 72:21-44 (*equally contributed)
  219. Pacetti P*, Giovannetti E *, Mambrini A, Nannizzi S, Del Tacca M, Cantore M, Danesi R (2009) Single nucleotide polymorphisms and clinical outcome in patients with biliary tract carcinoma treated with epirubicin, cisplatin and capecitabine. Anticancer Res 29:1835-1840 (*equally contributed)
  220. Tekle C*, Giovannetti E*, Sigmond J, Graaf J, Smid K, Peters GJ (2008) Molecular pathways involved in the synergistic interaction of the PKC-beta inhibitor enzastaurin with the antifolate pemetrexed in non-small-cell lung cancer cells. Br J Cancer 2008; 99:750-759. (*these authors equally contributed to the study)
  221. Lemos C, Kathmann I, Giovannetti E, Dekker H, Scheffer GL, Calhau C, Jansen G, Peters GJ (2008) Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in CaCo-2 cells. Int J Cancer 123:1712-1720
  222. Zucali PA, Gallegos Ruiz M, Giovannetti E, Destro A, Garcia M, Floor K, Ceresoli GL, Rodriguez JA, Roncalli M, Santoro A, Giaccone G. Role of cMET expression in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Ann Oncol 2008;19:1605-1612
  223. Funel N, Giovannetti E°, Del Chiaro M, Mey V, Boggi U, Pollina LE, Nannizzi S, Ricciardi S, Del Tacca M, Danesi R, Mosca F, Bevilacqua G, Campani D. Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma. Lab Invest 2008;88:7737-84 (°Corresponding author)
  224. Tibaldi C*, Giovannetti E*, Vasile E, Mey V, Nannizzi S, Laan AC, Orlandini C, Ricci S, Di Marsico R, Antonuzzo A, Del Tacca M, Peters GJ, Falcone A, Danesi R. Correlation of cytidine deaminase and DNA repair genes polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2008;14:1797-1803 (*these authors equally contributed to the study)
  225. Giovannetti E, Lemos C, Tekle C, Smid K, Nannizzi S, Rodriguez JA, Danesi R, Giaccone G, Peters GJ (2008) Molecular mechanisms underlying the synergistic interaction of erlotinib, an EGFR tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small cell lung cancer (NSCLC) cells. Mol Pharmacol 73:1290-1300
  226. Giovannetti E, Ugrasena DG, Supriyadi E, Vroling L, Azzarello A, de Lange D, Peters GJ, Veerman AJP, Cloos J. Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase promoter (TSER) polymorphisms in Indonesian children with and without Leukemia. Leuk Res 2008;32:19-24
  227. Giovannetti E, Backus HHJ, Wouters D, Peters GJ. Functional inactivity and mutations of p53 affect differently the sensitivity to 5-fluorouracil and antifolate inhibitors of thymidylate synthase (TS) by altering TS levels in colorectal cancer cells. Nucleosides Nucleotides Nucleic Acids 2008;27:740-745
  228. Giovannetti E, Laan AC, Vasile E, Tibaldi C, Nannizzi S, Ricciardi S, Danesi R, Falcone A, Peters GJ. Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. Nucleosides Nucleotides Nucleic Acids 2008;27:720-725
  229. Hubeek I, Peters GJ, Giovannetti E, Broekhuizen AJF, Pastor-Anglada M, Casado JF, Gibson BE, Creutzig U, Kaspers GJL. Expression of the nucleoside transporters hENT1 and hCNT1 in pediatric acute myeloid leukaemia. Nucleosides Nucleotides Nucleic Acids 2008;27:787-93
  230. Danesi R, Pasqualetti G, Giovannetti E, Del Tacca M.  The role of pharmacogenetics in adjuvant treatment of non-small-cell lung cancer. J Thorac Oncol 2007;2(5 Suppl):S27-30
  231. Giovannetti E, Backus HHJ, Wouters D, Ferreira CG, van Houten VMM, Brakenhoff RH, Poupon MF, Azzarello A, Pinedo HM, Peters GJ. Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels. Br J Cancer 2007;96:769-775
  232. Giovannetti E, Mey V, Loni L, Nannizzi S, Barsanti G, Savarino G, Del Tacca M, Danesi R. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells. Pharmacol Res 2007;5:343-349
  233. Bianco C*, Giovannetti E*, Ciardiello F, Mey V, Nannizzi S, Tortora G, Troiani T, Pasqualetti F, Eckhardt G, de Liguoro M, Del Tacca M, Raben D, Cionini L, Danesi R. Synergistic antitumor activity of ZD6474, an inhibitor of VEGFR and EGFR signaling, with gemcitabine and ionizing radiation against pancreatic cancer. Clin Cancer Res 2008;12:7099-7107 (*equally contributed); selected in the Highlights of the issue
  234. Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, Orlandini C, Boggi U, Campani D, Del Chiaro M, Iannopollo M, Bevilacqua G, Mosca F, Danesi R. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 2006;66:3928-3935
  235. Giovannetti E, Danesi R, Mey V, Nannizzi S, Pasqualetti G, Del Tacca M. In vitro studies on gemcitabine combinations with other antiblastics. Ann Oncol 2006;Suppl 5:v17-19
  236. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Del Tacca M, Danesi R. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol Cancer Ther 2006;5:1387-1395 S
  237. Mey V, Giovannetti E*, De Braud F, Nannizzi S, Curigliano G, Verweij F, De Cobelli O, Pece S, Del Tacca M, Danesi R. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. Br J Cancer 2006;95:289-297 (*Corresponding author)
  238. Giovannetti E, Mey V, Danesi R, Basolo F, Barachini S, Deri M, Del Tacca M. Interaction between gemcitabine and topotecan in human non-small cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile. Br J Cancer 2005;92:681-689
  239. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, Danesi R. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small cell lung cancer cells. Mol Pharmacol 2005;68:110-118
  240. Bengala C, Guarneri V, Giovannetti E, M Lencioni, Fontana E, V Mey, Fontana A, Boggi U, Del Chiaro M, Danesi R, Ricci S, Mosca F, Del Tacca M, Conte PF. Prolonged fixed dose rate infusion of gemcitabine with autologous hemopoietic support in advanced pancreatic adenocarcinoma. Br J Cancer 2005;93:35-40
  241. Minutolo F, Asso V, Bertini S, Betti L, Ciriaco M, Danesi R, Gervasi G, Ghilardi E, Giovannetti E, Giannaccini G, Placanica G, Prota G, Rapposelli S, Macchia M. Variously substituted (phosphonoacetamido)oxy analogues of geranylgeranyl diphosphate (GGdP) as GGdP-transferase (GGTase) inhibitors and antiproliferative agents. Med Chem 2005;1:239-44
  242. Giovannetti E, Mey V, Danesi R, Mosca I, Del Tacca M. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res 2004;10:2936-2946
  243. Macchia M, Antonello M, Bertini S, Di Bussolo V, Fogli S, Giovannetti E, Minutolo F, Rapposelli S, Danesi R. Conformationally restrained ceramide analogues: effects of lipophilic modification on the antiproliferative activity. Farmaco 2003;58:85-9
  244. Macchia M, Bertini S, Fogli S, Giovannetti E, Minutolo F, Rapposelli S, Danesi R. Ceramide analogues in apoptosis: a new strategy for anticancer drug development. Farmaco 2003;58:205-11
  245. Fogli S, Danesi R, De Braud F, De Pas T, Curigliano G, Giovannetti E, Del Tacca M. Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small cell lung cancer. Ann Oncol 2001;12:1553-1559
  246. Macchia M, Barontini S, Bertini S, Di Bussolo V, Fogli S, Giovannetti E, Grossi E, Minutolo F, Danesi R. Design, Synthesis, and Characterization of the Antitumor Activity of Novel Ceramide Analogues. J Med Chem 2001;44:3944-4000

Google Scholar: H-index=47, total number citations= 15870
53 articles as first and 80 as last name (12 corresponding author)
Total Impact factor (IF)>1500; Impact factor (IF) in 164 representative articles=1426 (average IF=8.693)

Conference Proceedings of JOP. J Pancreas (Online) – Journal Online

      1. Clinical and Translational Results of a Phase II Randomized Trial of Maintenance Sunitinib or Observation in Metastatic Pancreatic Adenocarcinoma. Belli C, Cereda S, Novarino A, Milella M, Passardi A, Di Lucca G, Mambrini A, Ferrari L, Danova M, Bergamo F, Franceschi E, GIOVANNETTI E, Rovati R, Gallà V, Balzano G, Ariotti R, Villa E, Reni M. J Pancreas (Online) 2012 Sep 20; 13(5 Suppl):551.
      2. PTEN and MIR-21 Expression in IPMN and PDAC. Alvino A, Botta L, Denaro M, Pollina LE, Perrone V, De Lio N, Caniglia F, Boggi U, Campani D, Funel N, GIOVANNETTI E. J Pancreas (Online) 2012 Sep 20; 13(5 Suppl):580.
      3. Synergistic Interaction of Novel Lactate Dehydrogenase Inhibitors with Gemcitabine in Hypoxic Models of Pancreatic Cancer. GIOVANNETTI E, Sciarrillo R, Granchi C, Leon LG, Funel N, Macchia M, Avan A, Minutolo F, Peters GJ. J Pancreas (Online) 2011 Oct 11; 12(5):513.
      4. Significant Association Between DNA Repair Polymorphisms and Survival in Pancreatic Cancer Patients Treated with Gemcitabine/Platinum Combination Chemotherapy. GIOVANNETTI E, Reni M, Pacetti P, Mambrini A, Vasile E, Lucchesi M, Ghidini M, Funel N, Avan A, Cereda S, Cantore M, Peters GJ. J Pancreas (Online) 2011 Oct 11; 12(5):514.
      5. MicroRNA-21: An Oncomir Under the Spotlight as a Potential Biomarker of Clinical Outcome and Determinant of Chemoresistance in Pancreatic Cancer. Giovannetti E, Funel N, Vasile E, Del Chiaro M, Leon LG, Erozenci LA, Pollina LE, Falcone A, Danesi R, Verheul HM, Boggi U, Peters GJ, Campani D. J Pancreas (Online) 2010 Sep 20; 11(5 Suppl):509.
      6. Molecular Mechanisms Underlying the Synergistic Interaction of the Novel Anticancer Drug Ukrain with Gemcitabine in Preclinical Models of Pancreatic Cancer. Funel N, Giovannetti E, Nowicky W, Pollina LE, Del Chiaro M, Nowicky B, Mosca F, Peters GJ, Campani D, Boggi U. J Pancreas (Online) 2010 Sep 20; 11(5 Suppl):524-525.
      7. Loss of Heterozygosity (LOH) Status of D9S105 Marker Is Associated with Down-Regulation of Kruppel-Like Factor 4 (KLF4) Expression in Pancreatic Ductal Adenocarcinoma and PanINs. Funel N, Morelli M, Giovannetti E, Pollina LE, Del Chiaro M, Bevilacqua G, Mosca F, Cavazzana A, Campani D, Boggi U J Pancreas (Online) 2010 Sep 20; 11(5 Suppl):506.
      8. Significant association between DNA repair polymorphisms and survival in pancreatic cancer patients treated with polychemotherapeutic regimens. Giovannetti E, Pacetti P, Reni M, Alecci C, Giancola F, Ghidini M, Mambrini A, Leon GL, Cereda S, Funel N, Orlandi M, Rezzonico S, Del Chiaro M, Danesi R, Peters GJ, Cantore M. J Pancreas (Online) 2009;10(5 Suppl):599.
      9. Selective Effect of Ukrain in Primary Pancreatic Tumor Cell Cultures. Funel N, Giovannetti E, Nowicky W, Pollina LE, Del Chiaro M, Peters GJ, Mosca F, Boggi U, Campani D. J Pancreas (Online) 2009;10(5 Suppl):616-617.
      10. Laser Microdissection (LMD) and Primary Cell Cultures Improve Pharmacogenetic Analysis in Pancreatic Adenocarcinoma, Allowing the Use of Gene Expression Levels and WHO Grading as Prognostic Markers. Funel N, Giovannetti E, Del Chiaro M, Pollina LE, Mey V, Boggi U, Salem AF, Nannizzi S, Del Tacca M, Bevilacqua G, Mosca F, Danesi R, Campani D. J Pancreas (Online) 2008;9(6 Suppl):812.
      11. Genes Involved in Gemcitabine Activity: Pancreas Cancer vs. Primary Cell Cultures. Funel N, Giovannetti E, Campani D, Pollina LE, Di Cristofano C, Mey V, Menicagli M, Nannizzi S, Morelli M, De Nisi MC, Danesi R, Del Chiaro M, Boggi U, Del Tacca M, Mosca F, Cavazzana A, Bevilacqua G. J Pancreas (Online) 2006;7(5 Suppl):534.
      12. Pharmacogenetics of Gemcitabine in Pancreatic Cancer. Giovannetti E, Mey V, Danesi R, Del Chiaro M, Funel N, Boggi U, Orlandini C, Campani D, Iannopollo M, Nannizzi S, Ricci S, Bevilacqua G, Mosca F, Del Tacca M.. J Pancreas (Online) 2004;6(5 Suppl):488-489.

Book chapters

    1. MicroRNAs in Diseases and Disorders: Emerging Therapeutic Targets. Chapter:  Modification of drug response in cancer by microRNAs. Meijer LL, Puik JR, Vivaldi C, Capula M, Vasile E. Kazemier G, GIOVANNETTI E (Editors, Dr Philip Peplow and Dr. George Calin) Royal Society of Chemistry 2018, in press
    2. Targeting Cell Survival Pathways to Enhance Response to Chemotherapy. Chapter: Targeting the Hepatocyte groth factor Receptor to Overcome Resistance to targeted Therapies. Van Der Steen N, Garajova I, Rolfo C, Cavazzoni A, GIOVANNETTI E (Editor, Daniel E. Johnson) Elsevier Publishing Company 2017
    3. Liquid Biopsies in Cancer patients: The Hand Lens for Tumor Evolution. Chapter 15: Liquid Biopsies in Esophageal, Gastric and Pancreatic Cancers. GIOVANNETTI E, Massinhia D, Barraco N, Listi A, Incorvaia L, Castiglia M, Russo A (Editors, Antonio Giordano, Antonio Russo, Christian Rolfo), Current Clinical Pathology Series (Series Editor: Antonio Giordano) Humana Press, US, 2017
    4. Immunotherapy. Chapter 5: Immunotherapy in NSCLC: A Promising and Revolutionary Weapon. Rolfo C, Caglevic C, Santarpia M, Araujo A, GIOVANNETTI E, Gallardo CD, Pauwels P, Mahave M. Adv Exp Med Biol. 2017;995:97-125. Advances in Experimental Medicine and Biology Series (Editors, Aung Naing, Joud Hajjar) Springer, US, 2017
    5. WDR48 (WD repeat domain 48). Olazabal-Herrero A, Peters GJ, GIOVANNETTI E. Rodriguez JA. Atlas Genet Cytogenet Oncol Haematol. April 2017
    6. Pancreatic cancer: Prevention, Detection, Treatment and translational research. Avan A, Maftouh M, Ghayour-Mobarhan M, Peters GJ, GIOVANNETTI E. Gastrointestinal Cancers: Prevention, Detection and Treatment, Nova Publisher 2016, in press
    7. CYB5A (Cytochrome B5 Type A (microsomal)). Gomez VE, Avan A, Peters GJ, GIOVANNETTI E. Atlas Genet Cytogenet Oncol Haematol. January 2016. Link:
    8. The role of microRNAs in resistance to current pancreatic cancer treatment: translational studies and basic protocols for extraction and PCR analysis. Garajová I, Le Large TY, GIOVANNETTI E, Kazemier G, Biasco G, Peters GJ. Methods in Molecular Biology – Cancer Drug Resistance, in press
    9. Pharmacology and clinical development of new molecularly targeted agents. Chapter 3: Targeted Therapies for Solid Tumors. GIOVANNETTI E, Galvani E (editors, Antonio Russo, Rafael Rosell, Christian Diego Rolfo), Springer Science Ed, New York, US, in press
    10. EZH2 (enhancer of zeste homolog 2). Avan A, Maftouh M, Fiuji H, GIOVANNETTI E, Peters GJ. Atlas Genet Cytogenet Oncol Haematol. March 2014
    11. USP1 (ubiquitin specific peptidase 1). García-Santisteban I, Peters GJ, Rodriguez JA, GIOVANNETTI E. Atlas Genet Cytogenet Oncol Haematol. October 2013.
    12. MIR211 (microRNA 211). Avan A, Maftouh M, Peters GJ, GIOVANNETTI E. Atlas Genet Cytogenet Oncol Haematol. May 2013.
    13. Analysis of drug interactions. Chapter 4.25: Cancer Cell Culture, Bijnsdorp IV, GIOVANNETTI E, Peters GJ. 2011, Humana Press Inc., in PubMed as Analysis of drug interactions. Bijnsdorp IV, GIOVANNETTI E, Peters GJ. Methods Mol Biol. 2011;731:421-34.
    14. Proteomics and genomics (Proteomica e genomica) Chapter in: Proteomics, genomics and development of new drugs. Danesi R, Di Paolo A, GIOVANNETTI E, Bocci G, Del Tacca M. 2007. Ed. Poletto Editore srl, Milano, Italy
    15. Molecular Therapy in Oncology (Terapia Molecolare in Oncologia) Chapter 4: Pharmacogenetics and Pharmacogenomics. Danesi R, GIOVANNETTI E, Pasqualetti G, Del Tacca M (editors, Dino Amadori and Carlo Maria Croce) 2005, Ed. Poletto Editore srl, Milano, Italy